Make Biotech Cash Considerations With SBIO

In financial markets, it’s often said that cash is king. That’s something to remember when it comes to the biotechnology universe due to the cost-intensive nature of developing new drugs and therapies. As a result, analysts and investors often monitor cash burn rates among biotech companies because...